This inventor holds 2 USPTO granted patents. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2008-2014.
Company Filing History:
Years Active: 2008-2014
Title: Michael Guetschow: Innovator in Angiogenesis Inhibition
Introduction
Michael Guetschow is a notable inventor based in Bonn, Germany. He has made significant contributions to the field of medical research, particularly in the development of thalidomide analogs as potential angiogenesis inhibitors. With a total of 2 patents, his work aims to enhance therapeutic options while minimizing adverse effects.
Latest Patents
Guetschow's latest patents focus on the development of analogs of thalidomide that exhibit superior anti-angiogenic properties. These patents detail the isolation and identification of various thalidomide metabolites that possess enhanced potency in inhibiting undesirable angiogenesis. The thalidomide analogs developed by Guetschow mimic the effects of these active metabolites, providing a promising avenue for therapeutic applications without the negative side effects associated with traditional thalidomide administration.
Career Highlights
Michael Guetschow is affiliated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work has been pivotal in advancing the understanding of angiogenesis and its implications in various medical conditions.
Collaborations
Guetschow has collaborated with notable colleagues such as Uwe Teubert and Kurt Eger. Their combined expertise has contributed to the innovative research and development of thalidomide analogs.
Conclusion
Michael Guetschow's contributions to the field of angiogenesis inhibition through his innovative patents highlight his role as a significant inventor. His work not only advances medical research but also opens new possibilities for effective treatments.